← Back to Search

Tyrosine Kinase Inhibitor

Serial Ultrasound for Kidney Cancer

N/A

Waitlist Available

Led By Alice C Fan, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pathology-confirmed diagnosis of metastatic RCC

18 years of age or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will look at whether changes in how blood flows through tumors after 3 weeks of treatment can predict whether the treatment is working at 12 weeks.

Who is the study for?

This trial is for adults with metastatic renal cell carcinoma (advanced kidney cancer) who are about to start treatment. They must have a tumor larger than 1 cm that can be seen on ultrasound and agree to the study's procedures. People with health issues that could interfere with their participation, as judged by the medical team, cannot join.

What is being tested?

The study tests if early changes in blood flow within tumors, measured by power doppler ultrasound after starting treatment, can predict how well patients will respond at 12 weeks. It compares two groups: one receiving VEGFR2 inhibitors plus immune therapy and another getting non-immune therapies.

What are the potential side effects?

Possible side effects from VEGFR2 inhibitors include high blood pressure, fatigue, diarrhea, mouth sores, hand-foot syndrome (redness and pain in hands/feet), and increased risk of bleeding or clotting events.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney cancer has spread to other parts of my body.

Select...

I am 18 years old or older.

Select...

I am planned to be treated with a specific drug combination for my condition.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Measure Initial Objective response

Secondary study objectives

Lesion response compared to baseline

Progression free survival (PFS)

Relative change in tumor burden compared to baseline

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Tyrosine kinase (TKI) inhibitor plus immune checkpoint inhibitor (ICI)Experimental Treatment3 Interventions

Patients are planned to be treated with vascular endothelial growth factor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)

Group II: Non-ICI therapyExperimental Treatment2 Interventions

Patients are planned to be treated with non-ICI therapy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Doppler Ultrasound

2019

N/A

~250

0 / 3Eligibility criteria met